Thiazide diuretics reduce overall mortality and the risk of stroke in patients with hypertension, and may be better than other treatments in elderly patients, where they may be superior to the betablockers in reducing end-points, 1 and in Afro-Caribbean patients.
Thiazide diuretics reduce overall mortality and the risk of stroke in patients with hypertension, and may be better than other treatments in elderly patients, where they may be superior to the betablockers in reducing end-points, 1 and in Afro-Caribbean patients. 2 The drugs are cheap, easy to take, and generally safe. Concerns about the metabolic adverse effects of thiazides, which can include lipid abnormalities, glucose intolerance and the precipitation of acute gout are more relevant to the relatively high doses used in the past than to the current lower doses, such as bendrofluazide 2.5 mg, which cause minor metabolic effects, if any, but are effective in reducing blood pressure. 3 Higher doses, even bendrofluazide 5 mg, do not confer any additional antihypertensive benefits but increase the risk of metabolic problems.
Nevertheless, a recent paper in the American Journal of Cardiology by Grossman, Messerli and Goldbourt 4 suggests that the long term use of diuretics in patients with hypertension is associated with an increased risk of renal cell carcinoma. Should this report change our views on the safety and efficacy of diuretics for hypertension? Their paper is an overview analysis of nine case-control studies and two cohort studies in which the relationship between diuretic use and renal cell carcinoma was examined. In the case-control studies, the odds ratio of renal cell carcinoma was 1.55 (95% confidence interval (CI) 1.42-1.71, P Ͻ 0.00001), whilst in the two cohort studies with more than 45 000 patients, treatment with diuretics resulted in a two-fold risk of renal cell carcinoma when compared to patients not on diuretics. Women apparently had a higher odds ratio of 2.01 (95% CI 1.56-2.67) than men (odds ratio 1.69, 95% CI 1.34 -3.13) of developing renal cell carcinoma. Three studies showed the risk of renal cell carcinoma to increase with the duration of diuretic therapy and cumulative dosage. The relationship also appeared to be present in normotensive patients who took diuretics for another reaCorrespondence: Dr GYH Lip, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK son, and persisted even after correction for the presence of hypertension, as the latter may perhaps itself be a risk factor for renal cell carcinoma. 5, 6 Meta-analysis, the art which Grossman and Messerli 4 employ, is an important way of reducing uncertainty due to random error, but does nothing to correct bias that is potentially present in all casecontrol studies. For example, recall bias, which would make patients with cancer of the kidney more likely to recall taking diuretics than patients with disorders unrelated to the urinary tract, is not corrected by meta-analysis. The analysis can itself be biased by collecting only some of the relevant studies. Notoriously, publication bias, a consequence of the natural desire of editors to publish positive results, can lead to a failure to include negative trials in the meta-analysis. Bias can also be introduced by seeking out only papers published in English, for example, or indexed in MEDLINE. Meta-analysis cannot correct for statistical confounding, either. In particular the effects of thiazides and the hypertension for which they are chiefly prescribed cannot be easily separated. These difficulties should introduce a note of scepticism at the outset.
If the odds ratios which Grossman and Messerli 1 calculate were real, the next question is whether they are of practical importance. They may not be. For example, a study which showed a doubling of the risk of being struck by lightning in those who go out without a hat, would probably not modify our behaviour. Lindblad et al 7 found an excess of 69 renal cell cancers in 115 616 patients taking diuretics for up to 20 years, implying one extra case of renal cell cancer for every 1500 patients.
Is the relationship plausible? Renal cell carcinoma develops from renal tubular cells, where diuretics exert their pharmacological effect, so there is a plausible anatomical link. There are also some animal data suggesting that diuretics can cause nephropathy and renal cell tumours in experimental models. 8, 9 One thiazide diuretic, hydrochlorothiazide, is a cyclic imide compound which can be converted to a carcinogenic nitroso derivative. The large studies used in this meta-analysis 4 have not generally distinguished between different thiazides, or even between thiazides and other diuretics. It should be noted also that many of the earlier studies used in the overview analysis considered subjects taking much higher doses of thiazides than would now be prescribed. It is difficult to see why women should be at higher risk from diuretics. Benichou et al 10 recently examined the 'population attributable risk' for renal cell cancer. They found that the overall risk of renal cell cancer was nearly twice as high in men, but that a higher proportion of the risk could be accounted for in women by three chief risk factors: smoking, hypertension (and its treatment), and obesity. The interactions between sex, obesity, and hypertension are not easy to disentangle, and likely to be important. Muscat et al 11 found that hypertensive women whose body mass index was in the top quartile had an odds ratio of 3 for renal cell cancer.
The possible association between hypertension and cancer is not a new concept. The debate goes through periods of intense activity alternating with lethargy. In 1981, data from the Western Electric Health Study suggested that a positive association between elevated blood pressure and risk of death from cancer was specific to death from renal cell carcinoma and epidermoid cancers of the head and neck. 12 Nevertheless, the authors suggested that the relationship between epidermoid head and neck cancer was probably indirect, resulting from the effects of alcohol consumption, whilst the relationship with kidney cancer was probably due to the effects of abnormal renal cell activity. A 5-year study in 4067 hypertensive patients and 10 366 normotensive patients from general practices in southwestern Ontario found an increased incidence of cancer among hypertensives, which was most pronounced amongst newly diagnosed hypertensive patients, especially if hypertension was moderate or severe. As the relationship appeared to be strongest in newly diagnosed hypertensive patients, the authors postulate that the causal of direction was from cancer to hypertension, rather than the reverse. 13 Nevertheless, Yeno et al 14 reported data from the Honolulu Heart Programme suggesting that there was no significant association of either systolic or diastolic blood pressure with cancer, in a multivariate analysis, amongst Japanese men in Hawaii. In the Glasgow Blood Pressure Clinic database, cancer mortality was also not significantly increased in clinic patients as a whole or controls; but there was an increase in the relative risk of renal cell cancer. 15 The same investigators recently reported that long term use of angiotensin-converting enzyme (ACE) inhibitors may actually protect against cancers in patients with hypertension. 16 Analgesic usage may be higher among women (and possibly more so amongst hypertensive women) and that is another potentially confounding factor, as analgesics may increase the risk of renal cell cancer. 7 Chow et al 17 showed a doubling of the odds ratio in women who took paracetamol, although this was not statistically significant in their sample. Grossman et al 4 have not considered the effects of smoking or obesity, nor do they have data on analgesic usage. The relation between antihypertensive agents and cancer risk may simply be spurious in view of the possible relationships between treated hypertension, obesity, analgesics, smoking, and cancer.
We should learn lessons from another recent epidemiological alarm which was sounded over the calcium antagonists. In particular, Pahor et al 18 suggested that calcium antagonists were associated with an increased risk of cancer in a prospective cohort study of 5052 patients aged 71 years or more when those taking calcium channel antagonists (n = 451) were compared to all other participants (n ϭ 4601). The hazard ratio for cancer associated with a calcium antagonist compared to those who were not taking these agents was 1.72 (95% CI 1.27 to 2.34). The Boston Collaborative Drugs Surveillance programme found a small positive association between calcium channel antagonists and the risk of cancer, but it was thought unlikely to be causal since there was no increase in risk with increasing duration of calcium channel antagonist use. 19 To add to the debate, the Glasgow Blood Pressure Clinic found no significant relationship between calcium antagonists and cancer. 20 A 10-year follow up of 2607 patients after acute myocardial infarction in the SPRING study did not find an increased risk of cancer mortality in patients treated with nifedipine. 21 The prospective Syst-Eur trial did not demonstrate any excess of cancers amongst the patients treated with the calcium antagonist, nitrendipine, but one could argue that the duration of follow-up was too short to demonstrate an effect, if any. 22 Once a suspicion has been raised by an epidemiological analysis, it is sometimes difficult to allay it, even though such studies cannot prove causality. While a demonstration that effects depend on dose, that they are consistent, and that the effect is large, can all reinforce the view that an association is more than mere chance: nevertheless, prospective, randomised, controlled trials are the final arbiters. If Grossman et al 4 are correct, then antihypertensive therapy with diuretics will prevent 20-40 strokes, 3-28 heart attacks, 3-10 cardiovascular deaths and 4 -14 deaths overall, for every extra case of renal cell carcinoma. In middle-aged women, diuretics would probably prevent six strokes, no heart attacks and no deaths for each (potential) case of renal cell carcinoma, assuming the data from Grossman et al 4 were accurate.
If diuretics are potential low-grade carcinogens, it is likely to take many years of treatment before a patient develops cancer, and many patients are unlikely to live long enough to manifest carcinomas. McLaughlin et al 23 suggested that no excess incidence of renal cell cancer was seen in those taking diuretics for less than 15 years. The absolute risk seems to be small, and the observed odds ratios could easily be explained by bias or confounding. For now, we would advocate no change in policy on the basis of the meta-analysis from the Ochsner Clinic, and certainly there is nothing yet to suggest the need for, or value of, routine surveillance. The strongest evidence on risk will come from prospective longitudinal trial data but it will be unlikely that such information will be available for the diuretics in one's lifetime from studies with sufficiently long follow-up to answer the question.
